» Articles » PMID: 36081590

The Challenging Management of Borderline Ovarian Tumors (BOTs) in Women of Childbearing Age

Abstract

Borderline ovarian tumors (BOTs) account for approximately 15% of all epithelial ovarian cancers. In 80% of cases the diagnosis of BOTs is done at stage I and more than a third of BOTs occurs in women younger than 40 years of age wishing to preserve their childbearing potential; the issue of conservative surgical management (fertility-sparing treatment) is thus becoming of paramount importance. At early stages, the modalities of conservative treatment could range from mono-lateral cystectomy to bilateral salpingo-oophorectomy. Although cystectomy is the preferred method to promote fertility it can lead to an elevated risk of recurrence; therefore, an appropriate counseling about the risk of relapse is mandatory before opting for this treatment. Nevertheless, relapses are often benign and can be treated by repeated conservative surgery. Besides the stage of the disease, histological subtype is another essential factor when considering the proper procedure: as most mucinous BOTs (mBOTs) are more commonly unilateral, the risk of an invasive recurrence seems to be higher, compared to serous histotype, therefore unilateral salpingo-oophorectomy is recommended. In the appraisal of current literature, this review aims to gain better insight on the current recommendations to identify the right balance between an accurate staging and an optimal fertility outcome.

Citing Articles

Unveiling a Large Pelvic Mass in a Middle-Aged Woman: The Consequences of Neglected Gynecological Care.

Anderson T, Carletto E, Burns B, Addison A Cureus. 2025; 16(12):e75789.

PMID: 39816315 PMC: 11734833. DOI: 10.7759/cureus.75789.


Molecular landscape of borderline ovarian tumours: A systematic review.

Sadlecki P, Walentowicz-Sadlecka M Open Med (Wars). 2024; 19(1):20240976.

PMID: 38859878 PMC: 11163159. DOI: 10.1515/med-2024-0976.


Conservative treatment of borderline ovarian tumors: a retrospective study.

Vaduva C, Constantinescu C, tenovici M, Boldeanu L, Istrate-Ofiteru A Rom J Morphol Embryol. 2023; 64(2):143-150.

PMID: 37518870 PMC: 10520401. DOI: 10.47162/RJME.64.2.03.


At what age endometriosis-associated ovarian cancer is diagnosed? The implications for women in the reproductive age.

Younis J, Izhaki I Front Oncol. 2023; 13:1193123.

PMID: 37287920 PMC: 10242000. DOI: 10.3389/fonc.2023.1193123.


Comparison of ultrasound-based ADNEX model with magnetic resonance imaging for discriminating adnexal masses: a multi-center study.

Hu Y, Chen B, Dong H, Sheng B, Xiao Z, Li J Front Oncol. 2023; 13:1101297.

PMID: 37168367 PMC: 10165107. DOI: 10.3389/fonc.2023.1101297.

References
1.
Benito V, Lubrano A, Arencibia O, Medina N, Alvarez Eva E, Andujar M . Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?. Eur J Obstet Gynecol Reprod Biol. 2010; 153(2):188-92. DOI: 10.1016/j.ejogrb.2010.07.024. View

2.
Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I . Management of borderline ovarian neoplasms. J Clin Oncol. 2007; 25(20):2928-37. DOI: 10.1200/JCO.2007.10.8076. View

3.
Iglesias D, Ramirez P . Role of minimally invasive surgery in staging of ovarian cancer. Curr Treat Options Oncol. 2011; 12(3):217-29. DOI: 10.1007/s11864-011-0155-3. View

4.
Cosentino F, Turco L, Cianci S, Fanfani F, Fagotti A, Gueli Alletti S . Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options. J Prenat Med. 2017; 10(1-2):8-14. PMC: 5505474. DOI: 10.11138/jpm/2016.10.1.008. View

5.
Kasaven L, Chawla M, Jones B, Al-Memar M, Galazis N, Ahmed-Salim Y . Fertility Sparing Surgery and Borderline Ovarian Tumours. Cancers (Basel). 2022; 14(6). PMC: 8946233. DOI: 10.3390/cancers14061485. View